Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt's B cell lymphoma

• Published in: Cancer cell international 2020-08, Vol.20 (1), p.375-375, Article 375
• Main Authors: Townsend, Michelle H, Ence, Zac E, Cox, Taylor P, Lattin, John E, Burrup, Weston, Boyer, Michael K, Piccolo, Stephen R, Robison, Richard A, O'Neill, Kim L
• Format: Article
• Language: English
• Subjects: Acute Lymphoblastic Leukemia; ALL; Antibodies; Antigens; B-cell lymphoma; Biomarkers; Biotinylation; Blood; BRCA1 protein; Burkitt’s B cell lymphoma; Cancer; Cell cycle; Confocal microscopy; CRISPR; Design; DNA biosynthesis; DNA repair; E-cadherin; Flow cytometry; Gene expression; Guanine; Hypoxanthine; Hypoxanthine Guanine Phosphoribosyltransferase (HPRT or HGPRT); Immunotherapy; Interleukin 6; Interleukin 6 receptors; Laboratories; Leukemia; Localization; Lymphatic leukemia; Lymphocytes; Lymphoma; Medical research; MSH2 protein; MSH6 protein; Non-Hodgkin's lymphoma; Patients; Phosphoribosyltransferase; Population; Primary Research; Proteins; Raji; Ribonucleic acid; RNA; Software; Western blotting
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-020-01457-8

The aim of this study is to determine whether Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) could be used as a biomarker for the diagnosis and treatment of B cell malignancies. With 4.3% of all new cancers diagnosed as Non-Hodgkin lymphoma, finding new biomarkers for the treatment of B cell cancers is an ongoing pursuit. HPRT is a nucleotide salvage pathway enzyme responsible for the synthesis of guanine and inosine throughout the cell cycle. Raji cells were used for this analysis due to their high HPRT internal expression. Internal expression was evaluated utilizing western blotting and RNA sequencing. Surface localization was analyzed using flow cytometry, confocal microscopy, and membrane biotinylation. To determine the source of HPRT surface expression, a CRISPR knockdown of HPRT was generated and confirmed using western blotting. To determine clinical significance, patient blood samples were collected and analyzed for HPRT surface localization. We found surface localization of HPRT on both Raji cancer cells and in 77% of the malignant ALL samples analyzed and observed no significant expression in healthy cells. Surface expression was confirmed in Raji cells with confocal microscopy, where a direct overlap between HPRT specific antibodies and a membrane-specific dye was observed. HPRT was also detected in biotinylated membranes of Raji cells. Upon HPRT knockdown in Raji cells, we found a significant reduction in surface expression, which shows that the HPRT found on the surface originates from the cells themselves. Finally, we found that cells that had elevated levels of HPRT had a direct correlation to XRCC2, BRCA1, PIK3CA, MSH2, MSH6, WDYHV1, AK7, and BLMH expression and an inverse correlation to PRKD2, PTGS2, TCF7L2, CDH1, IL6R, MC1R, AMPD1, TLR6, and BAK1 expression. Of the 17 genes with significant correlation, 9 are involved in cellular proliferation and DNA synthesis, regulation, and repair. As a surface biomarker that is found on malignant cells and not on healthy cells, HPRT could be used as a surface antigen for targeted immunotherapy. In addition, the gene correlations show that HPRT may have an additional role in regulation of cancer proliferation that has not been previously discovered.